Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLEODIAL-I: PXT00864 in Mild Alzheimer's Disease
NCT02361424Phase 2Completed
- Sponsor
- Pharnext
- Start
- Feb 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of acamprosate + baclofen in Alzheimer's disease (AD) (4 arms), sponsored by Pharnext. Primary endpoints: 11-item Alzheimer's Disease Assessment Scale- Cognitive Subscale at 12 weeks and Treatment Emergent Adverse Events at 12 weeks. Started Feb 2013; status: completed.
02
Drugs
acamprosate + baclofen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02361424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361424.